Listar por tema "Daclatasvir"

Mostrando ítems 1-2 de 2

Effectiveness and safety of daclatasvir/sofosbuvir with or without ribavirin in genotype 3 hepatitis C virus infected patients: results in real clinical practice

Margusino-Framiñán, Luis; Cid-Silva, Purificación; Mena, Álvaro; Rodríguez-Osorio, Iria; Pernas, Berta; Delgado, Manuel; Pértega-Díaz, Sonia; Martín-Herranz, Isabel; Castro-Iglesias, Ángeles (Sociedad Española de Quimioterapia, 2019)

[Abstract] OBJECTIVE: Direct-acting antivirals have shown high efficacy in all hepatitis C virus (HCV) genotypes, but genotype 3 (G3) treatments continue to be a challenge, mainly in cirrhotic patients. The aim of this ...
Effectiveness and safety of sofosbuvir‐based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis: results of a multicenter real‐life cohort

Alonso, S.; Riveiro-Barciela, M.; Fernández, I.; Rincón, D.; Real, Y.; Llerena, S.; Gea, F.; Olveira, A.; Fernández-Carrillo, C.; Polo, B.; Carrión, J.A.; Gómez, A.; Devesa, M.J.; Baliellas, Carme; Castro-Iglesias, Ángeles; Ampuero, J.; Granados, R.; Pascasio, J.M.; Rubín, A.; Salmerón, J.; Badia, E.; Planas, J.M.M.; Lens, S.; Turnes, J.; Montero, J.L.; Buti, M.; Esteban, R.; Fernández-Rodríguez, C.M. (Wiley, 2016-11-09)

[Abstract] Patients with HCV genotype 3 (GT3) infection and cirrhosis are currently the most difficult to cure. We report our experience with sofosbuvir+daclatasvir (SOF+DCV) or sofosbuvir/ledipasvir (SOF/LDV), with or ...